Evaluation of Anlotinib Metabolic Stability in HLMs Matrix Applying Ultra‐Fast UPLC–MS/MS Approach: Greenness Assessment With In Silico Testing for Structural Alarms Related to the Metabolic Lability and DEREK Toxicity
Biomedical Chromatography · 2025
DOI: 10.1002/bmc.70231 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2025. Verfasst von Mohamed W Attwa und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Microsomes, Liver, Indoles, Quinolines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: The Ongoing Research Funding program at King Saud University, Riyadh, Saudi Arabia.
Abstract (Originalsprache)
Anlotinib (Focus V) is approved by the China Centre for Drug Evaluation in 2018 as a third‐line treatment for patients with certain advanced cancers. This study aimed to develop a specific, fast, reliable, and sustainable ultraperformance liquid chromatography–tandem mass spectrometry (UPLC–MS/MS) approach for estimating anlotinib (ANB) in the human liver microsomes (HLMs) matrix, with the application for the assessment of ANB metabolic stability. The validation processes for the UPLC–MS/MS system complied with US Food and Drug Administration regulations following bioanalytical method validation. The established approach was validated using the HLMs matrix over the range of 1.0 to 4000 ng mL −1 within 1 min. The precision (%RSD) and accuracy (%E) rates for intra‐day and inter‐day measurements ranged from −6.33% to 4.91% and −6.67% to 5.26%, respectively. The StarDrop software package involved P450 and Deductive Estimation of Risk from Existing Knowledge modules that were applied for assessing metabolic lability and characterizing ANB structural alarms, respectively. The in vitro half‐life ( t ½ ) was computed at 44.72 min, while the clearance intrinsic (Cl int ) of ANB was calculated at 18.13 mL min −1 kg −1 . In silico evaluations suggest that minor structural alterations to the methyl group (62%), amine group (37%), and methoxy group (1%) in drug design may increase the ANB metabolic stability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
ORCID-Profile: Mohamed W Attwa, Ali S Abdelhameed
Förderung
- The Ongoing Research Funding program at King Saud University, Riyadh, Saudi Arabia
Zitieren
APA
Attwa, M. W., Abdelhameed, A. S., & Kadi, A. A. (2025). Evaluation of Anlotinib Metabolic Stability in HLMs Matrix Applying Ultra‐Fast UPLC–MS/MS Approach: Greenness Assessment With In Silico Testing for Structural Alarms Related to the Metabolic Lability and DEREK Toxicity. Biomedical Chromatography. https://doi.org/10.1002/bmc.70231
Vancouver
Attwa MW, Abdelhameed AS, Kadi AA. Evaluation of Anlotinib Metabolic Stability in HLMs Matrix Applying Ultra‐Fast UPLC–MS/MS Approach: Greenness Assessment With In Silico Testing for Structural Alarms Related to the Metabolic Lability and DEREK Toxicity. Biomedical Chromatography. 2025. doi:10.1002/bmc.70231
BibTeX
@article{Attwa2025,
author = {Attwa, Mohamed W and Abdelhameed, Ali S and Kadi, Adnan A},
title = {Evaluation of Anlotinib Metabolic Stability in HLMs Matrix Applying Ultra‐Fast UPLC–MS/MS Approach: Greenness Assessment With In Silico Testing for Structural Alarms Related to the Metabolic Lability and DEREK Toxicity},
journal = {Biomedical Chromatography},
year = {2025},
doi = {10.1002/bmc.70231}
}
EUVIMED